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Schlafen 14 (SLFN14) has recently been identified as an endoribonuclease responsible for
cleaving RNA to regulate and inhibit protein synthesis. Early studies revealed that members
of the SLFN family are capable of altering lineage commitment during T-cell differentiation
by using cell-cycle arrest as a means of translational control by RNase activity. SLFN14 has
been reported as a novel gene causing an inheritedmacrothrombocytopenia and bleeding in
human patients; however, the role of this endoribonuclease in megakaryopoiesis and
thrombopoiesis remains unknown. To investigate this, we report a CRISPR knock-in mouse
model of SLFN14 K208N homologous to the K219N mutation observed in our previous
patient studies. We used hematological analysis, in vitro and in vivo studies of platelet and
erythrocyte function, and analysis of spleen and bone marrow progenitors. Mice
homozygous for this mutation do not survive to weaning age, whereas heterozygotes exhibit
microcytic erythrocytosis, hemolytic anemia, splenomegaly, and abnormal thrombus
formation, as revealed by intravital microscopy, although platelet function and morphology
remain unchanged. We also show that there are differences in erythroid progenitors in the
spleens and bonemarrow of thesemice, indicative of an upregulation of erythropoiesis. This
SLFN14 mutation presents distinct species-specific phenotypes, with a platelet defect
reported in humans and a severe microcytic erythrocytosis in mice. Thus, we conclude that
SLFN14 is a key regulator in mammalian hematopoiesis and a species-specific mediator of
platelet and erythroid lineage commitment.
Introduction
Endoribonucleases are a family of proteins responsible for cleaving RNA to regulate and inhibit protein
synthesis.1 The Schlafen (SLFN) family of proteins/genes is made up of 10 mouse and 6 human SLFN
genes, all of which possess a characteristic AAA domain coding for DNA helicases, transcription
regulators, protein folding regions, and a distinctive SLFN box of unknown function.2 SLFN proteins are
divided into 3 subgroups and are highly homologous, classified based on their increasing length.
Subgroups II and III contain the aforementioned regions and a SWADL region, whereas subgroup III also
possesses an additional helicase region ; 400 aa.2-5
Reported roles for the SLFN family of proteins include translational control by RNase activity (SLFN14),
transfer RNA cleavage as part of the DNA damage response in tumor cells, and T-cell lineage and
commitment (SLFN1).6 Recently, SLFN14 mutations have been reported in 5 unrelated families
worldwide who present with macrothrombocytopenia and associated excessive bleeding.7-11 Patients
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with these mutations have a platelet function defect in response to
adenosine diphosphate, collagen, and PAR1-peptide and de-
creased platelet adenosine triphosphate secretion.7 Further in-
vestigation discovered that SLFN14 colocalizes with ribosomes and
causes endoribonucleolytic degradation of ribosomal RNA in
cells.12 These data, coupled with expression data from several
databases, suggest that SLFN14 is responsible for cleavage and
regulation of critical RNAs in megakaryocytic and erythroid differen-
tiation. Regulatory RNAs are thought to be critical in hematopoietic
lineage commitment, with unique RNA signatures reported in
multipotent and bipotent progenitors.13-15 Pisareva et al revealed
that SLFN14 is associated with cleaving RNA and ribosome-bound
messenger RNA (mRNA) in an Mg21-dependent and nucleotide
triphosphate (NTP)–independent manner.16 Recent evidence in
primary human cells from platelet and erythroid lineages suggests
that SLFN14 may function in a similar way in cleaving RNA from the
ribosomal unit prior to splitting, influencing hemoglobin production
during blood cell development.17
Despite these insights, the mechanistic role of SLFN14 in megakar-
yocyte (MK) development and hemostasis is unknown. To address this,
we generated a global CRISPR-mediated knock-in (KI) mouse
model of the patient mutation K219N missense substitution (mouse
K208N homolog), which is known to cause thrombocytopenia, and
investigated its overall role in hematopoiesis and platelet function.
Homozygous KI mice for this mutation (SLFN14K208N/K208N) did not
survive to weaning and, similarly, SLFN14 mutations identified in
humans are all of a heterozygous nature; therefore, heterozygous
mice were used in all experiments compared with litter-matched
wild-type controls (SLFN14K208N/1 and SLFN141/1, respectively).
We investigated the SLFN14 K208N mutation through hemato-
logical analysis, platelet activation, function, and its overall role in
hematopoiesis. SLFN14K208N/1 mice showed significant differ-
ences from SLFN141/1 mice in gross hematological analyses.
However, unlike the human variants, these mice demonstrate
a major defect in erythropoiesis but not megakaryopoiesis or
thrombopoiesis.
Differences in the consequences of this missense mutation suggest
that SLFN14 is a species-specific regulator of platelet and erythroid
lineage commitment. In humans, the mutation causes a defect in
thrombopoiesis, whereas a homologous missense mutation in mice
causes a significant defect in erythropoiesis. SLFN14K208N/1 mice
present with pronounced microerythrocytosis, hemolytic anemia,
splenomegaly, and abnormal thrombus formation in vivo.
Materials and methods
Mice
A SLFN14 K208N–KI mouse was generated in-house using CRISPR-
Cas9gene editing. All micewere generated on aC57BL/6J background
and were bred in heterozygote/wild-type pairs. Animal care and
welfare were in accordance with United Kingdom Home Office
regulations and the use of Animals (Scientific Procedures) Act
1986. Animals were housed at the Biomedical Services Unit at the
University of Birmingham.
Genotyping
All mice were genotyped in-house using DNA extraction from
mouse ear clips (DNeasy Blood & Tissue Kits; Qiagen, Manchester,
United Kingdom). Polymerase chain reaction (PCR) and Sanger
sequencing were used to identify SLFN14 K208N–KI mice
following the procedure and conditions outlined in supplemental
Tables 1 and 2.
Flow cytometry
Flow cytometry was performed on a BD Accuri C6 flow cytometer,
and results were analyzed using BD Accuri C6 software. Flow
cytometry antibodies are listed in supplemental Tables 4.
Platelet preparation
Mice were exsanguinated under terminal anesthesia by isoflurane/
O2 (5%) gas. Blood was drawn from the inferior vena cava, using
a 25-gauge needle, into 1:10 (volume-to-volume ratio) acid citrate
dextrose anticoagulant. Washed platelets were prepared as
described in supplemental Material.
Light transmission aggregometry
Washed platelet counts were normalized to 2 3 108/mL with
Tyrode’s-HEPES buffer. Aggregation in 300 mL of platelets was
measured using a lumi-aggregometer (Chrono-Log, Havertown,
PA) at 37°C under stirring conditions (1200 rpm) for 6 minutes
post–agonist addition.
Platelet spreading
Washed platelets at 23 107/mL were incubated for 45 minutes on
collagen-coated (10 mg/mL) and fibrinogen-coated (100 mg/mL)
coverslips under resting or preactivated conditions (0.1 U/mL
thrombin). Adhered cells were fixed with 10% formalin, permeabi-
lized, and stained with Alexa Fluor 488–conjugated phalloidin.
Images were captured on a Zeiss Epifluorescence microscope and
analyzed using a semiautomated machine learning–based
workflow.18,19
Hemostasis assay
All experiments were double blinded and conducted on 20 to 29g
SLFN14K208N/1 and litter-matched wild-type mice. Mice were
anesthetized using isoflurane/O2 (5%) gas, and 2 to 3 mm of tail tip
was excised using a sterile razor blade and placed in prewarmed
saline (37°C). Time until first cessation of bleeding was recorded.
Clot retraction
Platelet-rich plasma (PRP) from SLFN14K208N/1 and SLFN141/1
mice was adjusted to a final concentration of 2 3 108/mL using
platelet-poor plasma and Tyrode’s-HEPES buffer supplemented
with 2mM CaCl2, as previously described.
20 Erythrocytes were
added for visualization, and clot formation was stimulated by 1 U/mL
thrombin. Clots were monitored every 30 minutes for 2 hours, and
clot weight and volume were calculated.
In vivo thrombosis assays
Laser-induced injury of cremaster arterioles and FeCl3-induced
injury of carotid arteries were performed and analyzed as previously
described.21
Histological analysis
Spleens and decalcified bones were embedded in paraffin wax and
sectioned at 5 mm prior to staining with hematoxylin and eosin
(H&E) and Perls Prussian blue. Sections were scanned using
a Zeiss Axio ScanZ1 slide scanner (Carl Zeiss Ltd., Cambridge,
UK). The number of MKs was counted in 10 fields of view taken
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from 2 femur sections and 1 spleen section per mouse. Sectioning
and image analysis were performed double blinded.
Spleen and bone marrow progenitor flow cytometry
Spleens were homogenized and whole bone marrow was flushed
from mouse femurs and tibias in 1% fetal bovine serum and 2 mM
EDTA in phosphate-buffered saline. Cells were filtered through
a 70-mmcell strainer and stained with antibodies as per supplemental
Table 4. A total of 50000 events was collected using a BDAccuri C6
flow cytometer and gated to eliminate dead and cell doublets. Cells
were imaged on poly-L-lysine coated coverslips using a Zeiss
LSM880 confocal microscope.
Statistical analysis
Data are presented as mean 6 standard error of the mean (SEM),
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Figure 1. Generation of SLFN14 K208N mice using CRISPR-Cas9 gene editing and embryo development. (A) Schematic diagram of CRISPR-Cas9 gene-editing
mechanism using human K219N donor oligonucleotide. (B) Wild-type, SLFN14K208N/1, and SLFN14K208N/K208N traces showing successful KI of G.T missense mutation
(arrow). (C) Non-Mendelian inheritance pattern of SLFN14 K208N mice. x2 square analysis shows significant deviation from Mendelian inheritance and prewean loss of
homozygotes (P , .0001). Data are taken from 15 litters of heterozygote/heterozygote (cross 2) breeding pairs. (D) Representative images of backlit embryos taken at E12.5
and E14.5 (original magnification 33). n 5 3 to 9 embryos per genotype.








































































































































































































Figure 2. Hematological analysis of SLFN14K208N/1 mice. (A) Flow cytometry–based counting of platelets and erythrocytes. (Ai) Flow cytometry forward scatter (FSC)
and side scatter (SSC) plots showing size overlap of erythrocyte (red oval) and platelet (green oval) populations. (Aii) Gating method shown for double stain using CD41 (R2)
and Ter119 (R3). Representative plots of n 5 18 mice per genotype. (B) Platelet (PLT) (i) and erythrocyte (RBC) (ii) count and platelet (iii) and erythrocyte (iv) size from flow
cytometry–based counting. Data are mean 6 standard error of the mean (SEM); n 5 18 mice per genotype. (C) Immature platelet fraction in SLFN14K208N/1 mice. CD411
platelets were gated, and the immature platelet population was assessed by SYTO13 staining. Data are mean 6 SEM; n 5 13 to 20 mice per genotype. (D) Whole blood
smears from wild-type and SLFN14K208N/1 mice. Blood smears were stained with H&E histological stain to view blood cell size and morphology. Poikilocytes (irregularly
shaped cells; arrowheads) and microcytes (arrows) are shown. Representative images of n 5 6 or 7 mice per genotype. Scale bar, 10 mm. (E) SLFN14K208N/1 mice are
anemic. Hemoglobin levels were measured by an automated hematology analyzer in SLFN14K208N/1 mice and wild-type controls. Data are mean 6 SEM; n 5 23 to 26 mice
per genotype. *P , .05, ***P , .001, ****P , .0001.
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variance were used for platelet activation, and a Mann-Whitney U
test was used for in vivo analysis, with P , .05 deemed significant.
All analyses were conducted using GraphPad Prism software
(v8.4).
Animal care and welfare were in accordance with United Kingdom
Home Office regulations and the use of Animals in Scientific
Procedures Act 1986 under Project License number P53D52513
(to N.V.M.).
Results
SLFN14 K208N homozygotes do not survive to
weaning because of severe anemia
An in-house CRISPR-KI model was developed using homology
directed repair (HDR). Human oligonucleotide donor templates of
the K219N mutation were coinjected with single guide RNA as per
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Figure 3. In vitro assessment of platelet function in SLFN14K208N/1 mice. (A) Resting platelet surface glycoprotein expression levels. GP1ba1 platelets were costained for the
indicated surface receptors in whole blood. Median fluorescence intensity (MFI) from 4 to 6 mice per genotype. Data are mean 6 standard error of the mean (SEM); significance was
assessed using Welch’s t test for multiple comparisons. (B) P-selectin (i) and activated aIIbb3 (JON/A) (ii) expression on SLFN14K208N/1 mouse platelets in response to the indicated
agonist stimulation. Data are MFI (mean 6 SEM) for 9 mice per genotype per condition. Significance was assessed by Sidak’s 2-way analysis of variance. (C) Platelet reactivity in washed
platelets in response to 0.01 U/mL (i), 0.03 u/mL (ii), or 0.06 U/mL (iii) thrombin. (D) Platelet reactivity in washed platelets in response to 1 mg/mL (i) or 3 mg/mL (ii) collagen. (E) Platelet
reactivity in washed platelets in response 1 mg/mL (i), 3 mg/mL (ii), or 10 mg/mL (iii) collagen-related peptide. Representative traces of 3 to 6 mice per genotype per condition are shown.
(F) Platelet spreading and adhesion in SLFN14K208N/1 mice. SLFN14K208N/1 platelets spread on collagen or fibrinogen under resting and thrombin-preactivated conditions (0.1 U/mL
thrombin). Representative differential interference contrast and fluorescent phalloidin–stained images are shown from 3 mice per genotype/condition. Scale bar, 10 mm.
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G.T substitution and subsequent K208N amino acid change.
Sanger sequencing was used to genotype mice, with Figure 1B
showing successful KI of the mutation. A x2 analysis of
heterozygote/heterozygote breeding pairs shows significant
deviation from Mendelian inheritance, with ;25% of offspring lost
preweaning (P, .0001; Figure 1C). The average prewean loss was
25% across 15 litters, the same proportion of expected homozy-
gote offspring according to Mendel’s law (supplemental Table 3).
To assess embryonic lethality, embryos were gathered for observa-
tion and genotyping at 12.5 and 14.5 days post–vaginal plug. At
embryonic day 12.5 (E12.5), SLFN14K208N/1mice were not different
from wild-type littermates. However, SLFN14K208N/K208N embryos
were significantly paler, with less-defined vasculature (Figure 1D).
E14.5 SLFN14K208N/K208N embryos were much more pale, with
substantially less vascular definition than that seen in the other
genotypes (Figure 1D). No SLFN14K208N/K208N mice survived to
weaning for genotyping; therefore, we can deduce that if
SLFN14K208N/K208N pups do survive beyond the critical fetal
liver stage at day 14.5, they die shortly after birth. Therefore, in
parallel with K219N heterozygous patients, SLFN14 K208N
heterozygotes were used in analyses.
SLFN14K208N/1 mice have microcytic erythrocytosis,
poikilocytosis, and anemia
SLFN14K219N/1 patients exhibit macrothrombocytopenia; however,
we did not observe any difference in platelet count in homologous
SLFN14K208N/1 mice, but we did detect an increase in size using
a flow cytometry counting assay and single positive events of CD41
and Ter119–stained cells (Figure 2A,Bi-ii; P , .0001). Contrary to
the patient mutation, for which no effect on erythrocyte production
or function was reported, SLFN14K208N/1 mice exhibit microcytic
erythrocytosis, an increase in erythrocyte count accompanied by
a reduction in size (Figure 2Biii-iv). We did not observe any difference
in leukocyte counts between genotypes (data not shown).
SLFN14K219N/1 patients have a high immature platelet fraction
(IPF).7 We assessed IPF in SLFN14K208N/1 mice using a flow
cytometry method and nucleic acid stain SYTO13, which was
recently reported to be a more specific marker than its predecessor,
Thiazole orange.22 A 15% increase in the proportion of CD411
SYTO131 cells was observed in SLFN14K208N/1 mice compared
with SLFN141/1 controls (Figure 2C; P 5 .0003). Combined with
the observed increase in platelet size, these data indicate an
increase in the proportion of immature platelets in SLFN14K208N/1
mice.
Whole blood smears from SLFN14K208N/1 mice show irregularly
shaped smaller erythrocytes (poikilocytes and microcytes) compared
with the characteristic plump-shaped cells observed in wild-type
controls (Figure 2D). This microcytosis is accompanied by lower
hemoglobin levels in SLFN14K208N/1 mice (Figure 2E).
These results and previous work in T-cell lineage commitment
studies identify SLFNs as key drivers in species-dependent
hematopoietic lineage commitment. In this case, we observe
SLFN14 mutations causing distinct differences in platelet and
erythrocyte production and morphology.3,6
SLFN14K208N/1 mice exhibit normal platelet function
in response to major agonists
No alteration in major glycoprotein receptor levels was observed in
SLFN14K208N/1 platelets (Figure 3A). Platelet activation was
assessed by flow cytometry, and both genotypes displayed similar
a-granule secretion (P-selectin) and integrin aIIbb3 activation
(JON/A) in response to agonists at varying doses (Figure 3B).
Platelet function in SLFN14K208N/1 mice was assessed using light
transmission aggregometry. SLFN14K208N/1 mice display normal
platelet function compared with their wild-type littermates in
response to the agonists thrombin, collagen, and collagen-related
peptide (Figure 3C-E), which are mediated by G protein–coupled
receptors and ITAM/receptor tyrosine kinase, and are the 2 main
types of activation receptors in platelets.
We next investigated platelet adhesion and spreading on collagen-
or fibrinogen-coated surfaces. Under resting and preactivated
conditions, no difference in adhesion or cytoskeletal remodeling
was observed in SLFN14K208N/1 platelets (Figure 3F).18,19
Hemostasis and thrombosis in SLFN14K208N mice
SLFN14 patients were recruited to studies based on their bleeding
phenotypes. To establish whether SLFN14 transgenic mice had
a bleeding phenotype, 2 to 3 mm of tail tip was excised, and time to
bleeding cessation in prewarmed (37°C) saline was measured. No
difference was observed in either genotype, indicating that platelets
retain normal function, and abnormal erythrocytes do not impact
hemostasis in this model (Figure 4A).
Clot retraction was also investigated in PRP to assess aIIbb3-
mediated platelet function. No visual difference was observed
during the time course, and final mean clot weight of 36.0 mg and
30.0 mg for SLFN141/1 and SLFN14K208N/1 mice, respectively,
was not significantly different (Figure 4B). This supports our
findings that platelet function is maintained and that the SLFN14
K208N mutation in mice does not lead to platelet function defects.
Thrombus formation was assessed in vivo by laser- and FeCl3-
induced injury models. Following laser injury, SLFN14K208N/1 mice
Figure 4. Functional role of SLFN14 in thrombosis. (A) Tail bleeding time assay. Two to 3 millimeters of tail was removed, and bleeding time until first stop was measured.
Each data point represents 1 animal; n 5 18 to 20 mice per genotype. (B) Clot retraction of SLFN14K208N/1 mouse platelets in PRP. Clots were formed by stimulating
2 3 108 platelets per milliliter with 0.1 U/mL thrombin; monitoring took place for 2 hours. Representative images (Bi) and final clot weight (Bii). Data are mean 6 SEM; n 5 8
or 9 mice per genotype. (C) Laser-induced thrombus formation in vivo. (Ci) Representative composite brightfield and fluorescence images of thrombus formation. Mice were
injected with anti-GPIbb DyLight488 (0.1mg/g body weight). Arterioles of the cremaster muscle were subsequently injured by laser (arrowheads) and thrombi fluorescence was
measured. Scale bars, 10 mm. (Cii) Graph showing median integrated thrombus formation fluorescence intensity in arbitrary units (a.u.) for 31 or 32 injuries in 4 mice per
genotype. (D) FeCl3-induced thrombus formation. Mice were injected with DyLight488-conjugated anti-GPIbb antibody (0.1 mg/g body weight), and the carotid artery was
subsequently injured with 10% FeCl3 solution for 3 minutes. (Di) Representative fluorescence images of platelets (GPIbb). Scale bars, 200 mm. (Dii) Graph showing
median integrated thrombus fluorescence. (Diii) Area under the curve (AUC) of the integrated fluorescence density (in a.u). Data are mean; n 5 11 or 12 mice per genotype.
See supplemental Videos 3 and 4 for wild-type and mutants, respectively.
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Figure 5. SLFN14K208N/1 mice exhibit splenomegaly and extramedullary erythropoiesis. (Ai) Representative images of spleens from SLFN14K208N/1 and SLFN141/1
mice. (Aii) Normalized spleen weight. Spleen weight/body weight (mg/g) from 8 or 9 mice per genotype. (Bi) Representative images of H&E-stained spleen sections from
SLFN14K208N/1 and wild-type controls. Arrowheads indicate MKs. Scale bars, 50 mm. (Bii) Quantification of MK number per field of view. n 5 3 mice per genotype, 10 or 11
fields of view per tissue sample. Analysis was conducted blind. (C) Quantification of MKs in spleen. (Ci) MK staining: MKs were identified by CD41 (aIIb) allophycocyanin
(APC) and CD42 (GPIb) fluorescein isothiocyanate (FITC) double staining. (Cii) Proportion of MKs in spleen flow cytometry. (D) Quantification of erythroid progenitors in
spleen. (Di) ProE staining: ProEs were identified as double-positive CD71 (transferrin receptor 1) phycoerythrin (PE) and Ter119 FITC cells (ProE gate). (Dii) Quantification of
ProEs, increased Ter1191 cell population in SLFN14K208N/1 mice, and profile of Ter119hi cells by EryA, EryB, and EryC gates. (E) Quantification of MK-EB–primed MEPs in
the spleen: MEPs were identified as a small population positive for CD71 (transferrin receptor 1) PE and CD41 (aIIb) APC (MEP). (Ei) Flow cytometry plots show a slight, but
insignificant, increase in MEP cell numbers in SLFN14 K208N mice compared with wild-type. (Eii) MEP quantification. All spleen flow cytometry data and quantification are
representative of 4 or 5 mice per genotype/staining condition. (F) Representative images of hemosiderin deposits in spleen sections of wild-type and SLFN14K208N/1 mice
highlighted by Perls Prussian blue staining. Scale bars, 50 mm. n 5 3 mice per genotype. *P , .05, **P , .01, Student t test.
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form thrombi at a similar rate to SLFN141/1 controls, although they
are smaller, with fewer platelets recruited, and embolize more
quickly than do those in littermate controls (Figure 4C; supplemen-
tal Videos 1 and 2, respectively). FeCl3 injury to the carotid artery
resulted in occlusive thrombus formation in both genotypes
(Figure 4D; supplemental Videos 3 and 4). Monitoring the accumulation
of fluorescently labeled platelets shows thatSLFN14K208N/1mice form
thrombi at a slightly slower rate and have a tendency for reduced
stability, although these were not statistically different from littermate
controls (Figure 4Dii-iii). Ultimately, thrombus formation and stability
defects in SLFN14K208N/1 mice are driven by the involvement of other
blood cells; together with in vitro platelet function studies, these
findings suggest that SLFN14 K208N has only a minor role in mouse
platelets.
Splenomegaly in SLFN14K208N/1 mice is due to
extramedullary erythropoiesis, the accumulation of
mature erythrocytes, and hemolytic anemia
The spleen acts as a major site for filtering and clearance of blood
from the circulation. In classical findings of clearance, platelets
undergo phagocytosis controlled by their immunoglobulin
G–coated surfaces, rendering Fc receptor–directed clearance by
macrophages in the spleen.23 The spleen can also act as an
additional site of hematopoiesis in the event of myelofibrosis or
bone marrow scarring in certain pathologies.24 We investigated the
spleen to assess differences in blood cell production and clearance.
After controlling for body weight, spleens of SLFN14K208N/1 mice
were significantly larger with regard to weight and size compared
with those from SLFN141/1 littermates (Figure 5A). MK counts
from histology sections in the spleen were normal, and the
proportion of MKs was unchanged between genotypes by flow
cytometry analysis (Figure 5B-C).
Using a similar gating strategy to Koulnis et al, we used CD71 (early
erythroid progenitor marker) and Ter119 (mature erythroid marker)
to detect erythroid cells and categorized Ter119hi cells according
to size (Figure 5Di).25 There was a significant increase in the
proportion of proerythroblasts (ProEs) in heterozygotes (CD711
/Ter1191; Figure 5Dii). In these spleens, we did not detect any EryA
progenitors in either genotype (Figure 5D). However, despite fairly
consistent proportions of Ter119hi cells between genotypes, we
observed a difference in the distribution and greater spread of
CD711 cells within the EryB gate and an increase in EryCs (most
mature erythroid cells) in heterozygotes that was suggestive of
erythroid maturation from the intermediate progenitor within the
spleen (Figure 5D). Gating strategy for spleen flow cytometry is
detailed in supplemental Figure 1.
Our flow cytometry progenitor panel aimed to detect megakaryocyte-
erythroid progenitors (MEPs). Consistent with previous findings by
Psaila et al, we identified 2 subpopulations by differential expression of
CD71 and a small MEP population by coexpression of CD41.26
CD711/CD411 cells were rare in these samples, consistent with
previous findings, although we did detect an almost threefold increase
in MEPs in SLFN14K208N/1 mice than in wild-types26 (Figure 5E). In
addition, we observed a greater spread of cells within our CD711
population in contrast to the more clustered appearance in controls.
We discovered substantial hemosiderin staining in lysed eryth-
rocytes. These hemoglobin deposits occur naturally as a result of
macrophage-mediated clearance of erythrocytes. Using Perls
Prussian blue staining, we see a substantial increase in sites of
free heme staining, as indicated by the blue areas in Figure 5F.
Interestingly, we see staining in the red and white pulp of
SLFN14K208N/1 mice but only red pulp where macrophage
clearance occurs in controls. This is also supported by the color
difference in heterozygous spleens, which appear significantly
darker than SLFN141/1 spleens (Figure 5Ai). Here, we hypothesize
that erythropoiesis is accelerated to compensate for reduced
hemoglobin levels. We suggest that SLFN14K208N/1 erythrocytes
are more prone to hemolysis and that the spleen acts as a secondary
site of hematopoiesis, specifically upregulating erythropoiesis. The
spleen also acts in cell clearance; as such, it may be unable to
recognize the need for these additional erythrocytes in oxygen
transport which, in the case of SLFN14K208N/1 mice, may also be
the cause of accelerated hemolysis.
Bone marrow profiles showed significant alterations
in erythroid progenitors in SLFN14K208N/1 mice
The main site of hematopoiesis is the bone marrow; therefore, to
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leading to differences in platelet and erythrocyte counts, we
examined bone marrow sections and flow cytometry panels,
staining for progenitors. Double-blinded evaluation of bone marrow
histology sections revealed that MKs were highly populated within
the bone marrow, with morphology, including the characteristic
polyploid nuclei, consistent across the 2 genotypes (Figure 6A). We
analyzed progenitor levels in flushed whole bone marrow from
mouse femurs and tibias by flow cytometry. Live single cells were
selected based on size and forward scatter to detect progenitor
cells and subsequent double-positive populations (determined by
antibody staining) gated for analysis (supplemental Figure 2). MKs
were highlighted by CD411/CD421 events (MK quadrant); no
difference in the percentage of MKs was observed between
genotypes (Figure 6B).
Using CD71 and Ter119 as before, there was no significant
difference in the proportion of ProEs in the bone marrow (Figure
6Ci-ii). The percentage of Ter119hi cells was consistent between
SLFN14K208N/1 and wild-type mice; within this population, EryA,
EryB, and EryC populations were also unchanged between
genotypes (Figure 6Ci-ii). As in spleens, we observed the similar
“spread distribution” of variable CD71 expression within the EryB
gate; however, in contrast, mature erythrocytes (EryC) were rare.
Confocal imaging of this staining pattern is shown in Figure 6Cii.
The predecessor to MKs and ProEs is the MEP. Given the
differences that we observed in erythroid cell distribution
(Figure 6C) and evidence suggestive of a platelet defect in our
patient data, we detected megakaryocyte-erythroblast (MK-EB)–
primed MEPs using CD71 and CD41, as before. These double-
positive primed MEPs are often difficult to detect in situ within the
bone marrow (Figure 6Di).26 We did not observe any difference in
the proportion of CD711/CD411 cells in SLFN14K208N/1 mice
(Figure 6Dii). Confocal imaging supports an increase in cellular
events in the double-positive channel of heterozygotes and more
CD711 single-stained events (Figure 6Diii). The reason for this shift
in the MEP population is yet to be determined; however, we
hypothesize that it results from SLFN14K208N/1MK-EBMEPs being
more primed in the erythroid direction, consistent with higher single
CD71 positivity in this staining panel (CD711; Figure 6Di).
Increased CD711 staining may be expansion of the MEP with
preference towards the erythroid lineage, as well as due to
increased erythroid progenitors after this stage.
SLFN14K208N reduces GATA1 and SLFN14 mRNA
levels in hematopoietic cells
To examine whether the K208N mutation led to aberrant expression
in hematopoietic cells of SLFN14K208N/1 mice, we measured the
abundance of SLFN14 mRNA in whole bone marrow by real-time
quantitative PCR. Compared with RNA from wild-type controls,
SLFN14 mRNA levels were reduced significantly (by ;50%) in
SLFN14K208N/1 mice (P , .01; supplemental Figure 3).
Furthermore, we considered whether levels of the master transcrip-
tion factor GATA1 were altered as a result of the K208N mutation.
Real-time quantitative PCR was performed to measure GATA1
mRNA levels using cDNA-specific primers forGATA1 andGAPDH
as the endogenous control housekeeping gene.GATA1 levels were
reduced substantially in RNA from SLFN14K208N/1 mice compared
with litter-matched controls (P , .05; supplemental Figure 3). All
primers are given in supplemental Table 5.
Discussion
SLFN14 is a poorly studied endoribonuclease with suspected roles
in cleaving RNA that may contribute to a reported thrombocytope-
nia and clinical bleeding in multiple unrelated patients/families.
Here, we present a CRISPR KI mutation of K208N in mice and
establish the role of SLFN14 as a key player in the lineage-
commitment pathway, giving rise to species-specific phenotypes in
hematopoiesis. In this study, we analyzed heterozygous mutants,
because homozygous mutants did not survive to weaning and
showed significant deviation from Mendelian inheritance patterns.
This suggests that SLFN14 has a critical role in mouse
embryogenesis and, particularly, erythropoiesis. SLFN14 K208N
is likely to be particularly relevant in future studies of gene-
expression profiling in erythrocytes and anemia. E12.5 and E14.5
homozygous embryos were paler than their littermates, showed less
distinct vasculature, and did not survive to weaning. These are most
likely due to homozygotes’ more severe anemia and hemolysis that
results in death shortly after birth.27
The K208N mutation in mice presents with a different phenotype
than in its homologous human version, suggesting that it plays
a critical role at the MEP junction in lineage fate decisions. Previous
studies found that endoribonuclease function is critical in RNA
regulation in various bacterial species; however, to our knowledge,
Figure 6. Bone marrow progenitor profile of SLFN14K208N/1 mice. (Ai) Representative images of H&E-stained femur sections from SLFN14K208N/1 and SLFN141/1
mice. Femurs were fixed in 4% formaldehyde and decalcified before sectioning, staining and quantification of MK number per field of view. MKs are indicated by arrowheads.
Scale bars, 50 mm. (Aii) Quantification of MK number per field of view from 3 mice per genotype. Two femurs per mouse were sectioned, and 10 to 13 fields of view per
section were quantified blind. Students t test was used to assess significance. (B) Quantification of MKs in bone marrow. (Bi) MK staining: MKs were identified by CD41 (aIIb)
allophycocyanin (APC) and CD42 (GPIb) fluorescein isothiocyanate (FITC) double staining. (Bii) Quantification of MKs in whole bone marrow by flow cytometry. (C) Quantifica-
tion of erythroid progenitors in bone marrow. (Ci) ProE staining: ProEs were identified as double-positive CD71 (transferrin receptor 1) phycoerythrin (PE) and Ter119 FITC
cells (ProE gate). Maturation of ProEs to mature erythrocytes can be monitored by Ter119hi expression and loss of CD71 expression (EryB and EryC gates). Note the spread
of intermediate cells in EryBs, supporting evidence for an altered EryB fate in heterozygotes. (Cii) Quantification of erythroid progenitors in the bone marrow. (Ciii) Confocal
images of flow cytometry samples show a double-positive ProE population. Ter119 Alexa Fluor 488 and CD71 Alexa Fluor 647 and DAPI counterstain. Scale bars, 50 mm. (D)
Quantification of MEPs in bone marrow. (Di) MK-EB–primed MEPs: MEPs were identified as a small population positive for CD71 (transferrin receptor 1) PE and CD41 (aIIb)
APC (MEP). Flow cytometry plots show a slight, but insignificant, increase in MEP cell numbers in SLFN14 K208N mice compared with wild-types. (Dii) MEP quantification in
the bone marrow. Staining for these markers highlights MEP cells preferential to the MK or EB lineage. (Diii) Representative images of CD41 Alexa Fluor 488 and CD71 Alexa
Fluor 647 stained bone marrow cells imaged by confocal microscopy and using DAPI counterstain. Scale bars, 50 mm. All bone marrow flow cytometry data and quantifica-
tions are representative of 4 to 6 mice per genotype/staining condition.
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this is the first discovery of endoribonuclease-mediated species
differences in mammals.28,29
SLFN14K219N patients have a high IPF, suggesting that thrombo-
poiesis is not sufficient to maintain steady levels of platelet
production or that platelet clearance is accelerated. Platelets
contain residual RNA from their predecessors, MKs, which form
beaded extensions into the lumen of bone marrow sinusoids
(proplatelets) and subsequent shear forces of the bloodstream that
cause release of preplatelets and platelets into the blood.30 RNA
content can be used to estimate the rate of thrombopoiesis and
platelet turnover by measuring the proportion of reticulated platelets
within the circulation. An elevated platelet RNA content signifies
newer platelets in the circulation that was previously shown to
increase platelet reactivity in cardiovascular events and mortality.31
In the case of SLFN14K208N/1mice, we infer that the slight increase
in platelet size is due to their immaturity (determined by SYTO13
staining), but this is not accompanied by increased platelet
reactivity, as shown in our in vitro and in vivo experiments.
Although no platelet defects were observed in in vitro functional
studies, SLFN14K208N/1 mice exhibited reduced thrombus forma-
tion in vivo. These defects in the formation and stability of in vivo
thrombi are likely attributable to the abnormal erythrocytes in these
mice. Erythrocytes are the primary determinant of blood rheology
and promote platelet margination, increasing their concentration
near endothelium to enable rapid formation of thrombi in response
to vessel damage.32-34 Indeed, previous studies have shown reduced
thrombus formation and extended bleeding times in anemic mice.35
Although we did not observe altered hemostasis in SLFN14K208N/1
mice, changes in the size and number of erythrocytes may explain
thrombosis findings. Erythrocyte contribution to platelet activation
and thrombin generation should also be taken into consideration,
together with their unusual role supporting platelet adhesion in the
FeCl3 model.
35-37 Although SLFN14 patients display excessive
bleeding phenotypes, we do not report these similarities in mice.7
Bleeding in SLFN14 patients has been characterized and explained
by defects in platelet aggregation, but little to no effect on platelet
function was found in SLFN14K208N/1 mice. We believe that this
work precedes what is to become extensive research into platelet-
erythrocyte interactions in health and disease and reveals potential
novel mechanisms in hemolysis and anemia.
In SLFN14K208N/1 mice, we understand that the spleen acts as
a secondary site for erythropoiesis. Here, intermediate progenitors
(EryBs) differentiate into mature erythrocytes (EryCs), which are
highly populated within the spleen. Loss of CD71 expression is
indicative of erythrocyte maturation, and the “spread” appearance
of EryB cells in heterozygotes clearly shows this maturation phase.
This enhanced erythropoiesis is likely due to severe anemia and
hemolysis in these mice attempting to compensate for lower
hemoglobin levels. The following questions then arise: at what stage
in hematopoiesis do SLFN14 and its mutations cause a shift in
lineage commitment to platelet or erythroid directions and how, as
an endoribonuclease, does SLFN14 mediate this transition? Our
bone marrow flow cytometry data did not show any difference in bone
marrow MK, ProE, or MEP numbers, but there are discrepancies
within progenitors of the erythroid lineage suggesting that, in
hematopoiesis, SLFN14K208N/1 leads to altered erythropoiesis and
defects in erythroid cells. In the bone marrow, SLFN14K208N/1
Ter119hi cells expressing CD71 also showed variable expression
within the EryB gate, whereas wild-type cells present a more
clustered distribution. Platelets and erythrocytes originate from
a common progenitor; therefore, pinpointing the exact location of
this shift is notoriously difficult. However, we believe that using RNA-
sequencing of SLFN14 progenitors (MKs, ProEs, and MK/EB-MEPs)
will reveal discrepancies in RNA expression profiles to support our
preliminary findings that a reduction in GATA1 mRNA is specifically
involved in erythroid development. Future work will establish the
mechanistic effects of these mutations on human and murine RNA
signatures that are critical in lineage commitment. This will uncover
novel insights into SLFN14’s ability to cleave RNAs which perturb
RNA metabolism and protein synthesis in MK and erythroid lineages
in a species-dependent manner.
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